ClearPoint Neuro Q4 2025 prelim revenue $10.4M (+20% YoY); FY2026 guidance $54-60M

ClearPoint Neuro, Inc.

2025-FY EPS reported -$0.90 vs consensus -$0.20 ▼ miss (-341.2%)

Q4 2025 preliminary unaudited revenue ~$10.4M, 20% comparable sales growth over Q4 2024, excluding recent IRRA flow acquisition.
Full year 2025 preliminary revenue ~$37M.
FY2026 revenue guided at $54-60M, driven by organic growth and IRRA flow product integration.
Q4 segment growth: functional neurosurgery disposables +23%, biologics/drug delivery +26%.
Preliminary results subject to revision; audited results expected later in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.